High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing.

[1]  Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications , 2018, Nature Reviews Drug Discovery.

[2]  N. Kotov,et al.  Three-dimensional cell culture matrices: state of the art. , 2008, Tissue engineering. Part B, Reviews.

[3]  L. Kraus-Berthier,et al.  Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  F. Colpaert,et al.  Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid , 1998, Cancer Chemotherapy and Pharmacology.

[5]  D. Grainger,et al.  A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. , 2012, Pharmacology & therapeutics.

[6]  Ming-Rong Zhang,et al.  High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment. , 2015, Biomaterials.

[7]  Denis Wirtz,et al.  Hypoxia and the extracellular matrix: drivers of tumour metastasis , 2014, Nature Reviews Cancer.

[8]  C. Verbeke,et al.  3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing , 2013, BMC Cancer.

[9]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[10]  Robert M. Plenge,et al.  Disciplined approach to drug discovery and early development , 2016, Science Translational Medicine.

[11]  Andrew L. Kung,et al.  Examining the utility of patient-derived xenograft mouse models , 2015, Nature Reviews Cancer.

[12]  Shuichi Takayama,et al.  384 hanging drop arrays give excellent Z‐factors and allow versatile formation of co‐culture spheroids , 2012, Biotechnology and bioengineering.

[13]  C. Lovitt,et al.  Miniaturized three-dimensional cancer model for drug evaluation. , 2013, Assay and drug development technologies.

[14]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[15]  A. Napper,et al.  Beta-hairpin hydrogels as scaffolds for high-throughput drug discovery in three-dimensional cell culture. , 2017, Analytical biochemistry.

[16]  Serena M Best,et al.  Investigating the morphological, mechanical and degradation properties of scaffolds comprising collagen, gelatin and elastin for use in soft tissue engineering. , 2012, Journal of the mechanical behavior of biomedical materials.

[17]  J. Takagi,et al.  Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. , 2018, Cell stem cell.

[18]  R. Jain,et al.  Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.

[19]  Hans Clevers,et al.  A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity , 2018, Cell.

[20]  G. Viglietto,et al.  The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib , 2006, Journal of cellular physiology.

[21]  G. Xiong,et al.  Function of cancer cell-derived extracellular matrix in tumor progression , 2016 .

[22]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[23]  B. Cho,et al.  Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. , 2016, Lung cancer.

[24]  Moo-Yeal Lee,et al.  Biocompatible Hydrogels for Microarray Cell Printing and Encapsulation , 2015, Biosensors.

[25]  Yinzhi Lai,et al.  Three-dimensional polymer scaffolds for high throughput cell-based assay systems. , 2008, Biomaterials.

[26]  Daniel J. Maltman,et al.  Developments in three-dimensional cell culture technology aimed at improving the accuracy of in vitro analyses. , 2010, Biochemical Society transactions.

[27]  Y. Kodera,et al.  Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis , 2006, British Journal of Cancer.

[28]  P. Netti,et al.  3D is not enough: Building up a cell instructive microenvironment for tumoral stroma microtissues. , 2017, Acta biomaterialia.

[29]  Liju Yang,et al.  Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins , 2016, PloS one.

[30]  M. Raghunath,et al.  Electro-spinning of pure collagen nano-fibres - just an expensive way to make gelatin? , 2008, Biomaterials.

[31]  David Sidransky,et al.  Patient-derived xenografts for individualized care in advanced sarcoma , 2014, Cancer.

[32]  M. Ferrer,et al.  Three-Dimensional Cell Culture Assays: Are They More Predictive of In Vivo Efficacy than 2D Monolayer Cell-Based Assays? , 2015, Assay and drug development technologies.

[33]  D. H. Randle,et al.  Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening? , 2015, Assay and drug development technologies.

[34]  Bon-Kyoung Koo,et al.  Human Primary Liver Cancer -derived Organoid Cultures for disease modelling and drug screening , 2017, Nature Medicine.

[35]  Yunjung Choi,et al.  Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. , 2009, Lung cancer.

[36]  F. Gasparri,et al.  The development of high-content screening (HCS) technology and its importance to drug discovery , 2016, Expert opinion on drug discovery.

[37]  G. Peters,et al.  Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.

[38]  Yanan Du,et al.  Micro-scaffold array chip for upgrading cell-based high-throughput drug testing to 3D using benchtop equipment. , 2014, Lab on a chip.

[39]  Yasunosuke Suzuki,et al.  Short, thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence. , 2005, International journal of hygiene and environmental health.

[40]  L. O’Driscoll,et al.  Three-dimensional cell culture: the missing link in drug discovery. , 2013, Drug discovery today.

[41]  John W Haycock,et al.  3D cell culture: a review of current approaches and techniques. , 2011, Methods in molecular biology.

[42]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[43]  A. IJzerman,et al.  Label-free technology and patient cells: from early drug development to precision medicine. , 2017, Drug discovery today.

[44]  B. Thierry,et al.  Quasi-spherical microwells on superhydrophobic substrates for long term culture of multicellular spheroids and high throughput assays. , 2014, Biomaterials.

[45]  A. Corti,et al.  Improving drug penetration to curb tumor drug resistance. , 2012, Drug discovery today.

[46]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[47]  M. Vincenti,et al.  Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. , 2002, Urologic oncology.

[48]  A. Villanueva,et al.  The future of patient-derived tumor xenografts in cancer treatment. , 2015, Pharmacogenomics.

[49]  Liju Yang,et al.  Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. , 2014, Assay and drug development technologies.

[50]  Stefania Forti,et al.  New insights into the role of extracellular matrix during tumor onset and progression , 2002, Journal of cellular physiology.

[51]  F. Ciardiello,et al.  Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition , 2014, Clinical Cancer Research.

[52]  Anne E Carpenter,et al.  Increasing the Content of High-Content Screening , 2014, Journal of biomolecular screening.

[53]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[54]  Roland Eils,et al.  Screening drug effects in patient‐derived cancer cells links organoid responses to genome alterations , 2017, Molecular systems biology.

[55]  C. Takimoto.  Anticancer drug development at the US National Cancer Institute , 2003, Cancer Chemotherapy and Pharmacology.

[56]  M. Campiglio,et al.  Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling , 2008, Breast Cancer Research and Treatment.

[57]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[58]  3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response , 2016, BMC Cancer.

[59]  Yang Zeng,et al.  Biomechanically primed liver microtumor array as a high-throughput mechanopharmacological screening platform for stroma-reprogrammed combinatorial therapy. , 2017, Biomaterials.

[60]  Deepti Singh,et al.  Synthesis of composite gelatin-hyaluronic acid-alginate porous scaffold and evaluation for in vitro stem cell growth and in vivo tissue integration. , 2014, Colloids and surfaces. B, Biointerfaces.

[61]  R L Reis,et al.  A novel hanging spherical drop system for the generation of cellular spheroids and high throughput combinatorial drug screening. , 2015, Biomaterials science.

[62]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[63]  M. López-Caballero,et al.  Functional and bioactive properties of collagen and gelatin from alternative sources: A review , 2011 .

[64]  Elias A. Rivera,et al.  Cross‐linked gelatin microspheres with continuously tunable degradation profiles for renal tissue regeneration , 2014, Biotechnology and applied biochemistry.

[65]  Frank McCormick,et al.  AKT inactivation causes persistent drug tolerance to EGFR inhibitors. , 2015, Pharmacological research.

[66]  S. Sant,et al.  The production of 3D tumor spheroids for cancer drug discovery. , 2017, Drug discovery today. Technologies.

[67]  A. Nowak,et al.  A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice , 2017, BMC Cancer.

[68]  Jenny C. Chang,et al.  Patient-derived breast tumor xenografts facilitating personalized cancer therapy , 2013, Breast Cancer Research.